A Global, Open-Label, Multicenter, Phase 1/2 Study of the Safety and Dose Escalation of BAX 888, an Adeno-Associated Virus Serotype 8 (AAV8) Vector Expressing B-Domain Deleted Factor VIII (BDD-FVIII) in Severe Hemophilia A Subjects Administered a Single Intravenous Infusion
Phase of Trial: Phase I/II
Latest Information Update: 17 Aug 2018
At a glance
- Drugs SHP 654 (Primary)
- Indications Haemophilia A
- Focus Adverse reactions
- Sponsors Baxalta
- 31 Aug 2018 Biomarkers information updated
- 30 Jan 2018 Status changed from not yet recruiting to recruiting.
- 18 Jan 2018 Planned initiation date changed from 30 Dec 2017 to 31 Jan 2018.